Marine macroalga-associated heterotrophic Bacillus velezensis: a novel antimicrobial agent with siderophore mode of action against drug-resistant nosocomial pathogens.

Increased prevalence of microbial resistance and development of drug-resistant pathogens have triggered an urge among researchers to discover potential antimicrobial compounds, particularly from the marine habitat. The present study highlights the cultivable diversity and bioactivities of heterotrophic bacteria associated with marine macroalgae of southeast Indian coastal region. Culture-dependent isolation method resulted in 40 isolates, in which greater part of the isolates represented Gammaproteobacteria (62%) followed by that comprised of the phylum Firmicutes.

Marine macroalga-associated heterotroph Bacillus velezensis as prospective therapeutic agent.

Marine macroalgae and their accompanying microbial flora were proved to be the reservoir of potential bioactive compounds with promising pharmacological applications. Heterotrophic bacteria concomitant with the marine algae were isolated and screened for their antibacterial potential against clinically recognized pathogens. The bacterial isolate with greater bioactive properties was identified as Bacillus velezensis MBTDLP1 (phylum Firmicutes), which was isolated from the marine macroalga Laurencia papillosa, by integrated morphological, biochemical and molecular characterization.